Search

Your search keyword '"Lin, Chuan-Hao"' showing total 134 results
Start Over Author "Lin, Chuan-Hao"
134 results on '"Lin, Chuan-Hao"'

1. Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Author

Miethke, Alexander G, Moukarzel, Adib, Porta, Gilda, Covarrubias Esquer, Joshue, Czubkowski, Piotr, Ordonez, Felipe, Mosca, Antonella, Aqul, Amal A, Squires, Robert H, Sokal, Etienne, D'Agostino, Daniel, Baumann, Ulrich, D'Antiga, Lorenzo, Kasi, Nagraj, Laborde, Nolwenn, Arikan, Cigdem, Lin, Chuan-Hao, Gilmour, Susan, Mittal, Naveen, Chiou, Fang Kuan, Horslen, Simon P, Huber, Wolf-Dietrich, Jaecklin, Thomas, Nunes, Tiago, Lascau, Anamaria, Longpre, Lara, Mogul, Douglas B, Garner, Will, Vig, Pamela, Hupertz, Vera F, Gonzalez-Peralta, Regino P, Ekong, Udeme, Hartley, Jane, Laverdure, Noemie, Ovchinsky, Nadia, and Thompson, Richard J

Published
2024
Full Text
View/download PDF

2. Detecting Change Signs with Differential MDL Change Statistics for COVID-19 Pandemic Analysis

Author

Yamanishi, Kenji, Xu, Linchuan, Yuki, Ryo, Fukushima, Shintaro, and Lin, Chuan-hao

Subjects
Statistics - Applications, Computer Science - Information Theory, Statistics - Methodology
Abstract

We are concerned with the issue of detecting changes and their signs from a data stream. For example, when given time series of COVID-19 cases in a region, we may raise early warning signals of outbreaks by detecting signs of changes in the cases. We propose a novel methodology to address this issue. The key idea is to employ a new information-theoretic notion, which we call the differential minimum description length change statistics (D-MDL), for measuring the scores of change sign. We first give a fundamental theory for D-MDL. We then demonstrate its effectiveness using synthetic datasets. We apply it to detecting early warning signals of the COVID-19 epidemic. We empirically demonstrate that D-MDL is able to raise early warning signals of events such as significant increase/decrease of cases. Remarkably, for about $64\%$ of the events of significant increase of cases in 37 studied countries, our method can detect warning signals as early as nearly six days on average before the events, buying considerably long time for making responses. We further relate the warning signals to the basic reproduction number $R0$ and the timing of social distancing. The results showed that our method can effectively monitor the dynamics of $R0$, and confirmed the effectiveness of social distancing at containing the epidemic in a region. We conclude that our method is a promising approach to the pandemic analysis from a data science viewpoint. The software for the experiments is available at https://github.com/IbarakikenYukishi/differential-mdl-change-statistics. An online detection system is available at https://ibarakikenyukishi.github.io/d-mdl-html/index.html

Published
2020

3. Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection

Author

Rosenthal, Philip, Schwarz, Kathleen B, Gonzalez‐Peralta, Regino P, Lin, Chuan‐Hao, Kelly, Deidre A, Nightingale, Scott, Balistreri, William F, Bansal, Sanjay, Jonas, Maureen M, Massetto, Benedetta, Brainard, Diana M, Hsueh, Chia‐Hsiang, Shao, Jiang, Parhy, Bandita, Davison, Suzanne, Feiterna‐Sperling, Cornelia, Gillis, Lynette A, Indolfi, Giuseppe, Sokal, Etienne M, Murray, Karen F, and Wirth, Stefan

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Hepatitis - C, Hepatitis, Liver Disease, Clinical Trials and Supportive Activities, Infectious Diseases, Chronic Liver Disease and Cirrhosis, Clinical Research, Emerging Infectious Diseases, Pediatric, Digestive Diseases, Management of diseases and conditions, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 7.1 Individual care needs, Infection, Good Health and Well Being, Antiviral Agents, Child, Child, Preschool, Drug Combinations, Female, Genotype, Hepacivirus, Hepatitis C, Chronic, Humans, Male, Ribavirin, Sofosbuvir, Sustained Virologic Response, Treatment Outcome, Medical Biochemistry and Metabolomics, Immunology, Gastroenterology & Hepatology, Clinical sciences
Abstract

Currently, the only approved hepatitis C virus (HCV) treatment for children aged

Published
2020

4. Sofosbuvir–velpatasvir in children 3–17 years old with hepatitis C virus infection.

Author

Jonas, Maureen M., Romero, Rene, Rosenthal, Philip, Lin, Chuan‐Hao, Verucchi, Gabriella, Wen, Jessica, Balistreri, William F., Whitworth, Suzanne, Bansal, Sanjay, Leung, Daniel H., Narkewicz, Michael R., Gonzalez‐Peralta, Regino P., Mangia, Alessandra, Karnsakul, Wikrom, Rao, Girish S., Shao, Jiang, de Jong, Jan, Parhy, Bandita, Osinusi, Anu, and Kersey, Kathryn

Published
2024
Full Text
View/download PDF

6. Analysis of safety in maralixibat-treated participants with progressive familial intrahepatic cholestasis: data from MARCH-PFIC

Author

Miethke, Alexander, primary, Moukarzel, Adib, additional, Porta, Gilda, additional, Esquer, Joshue Covarrubias, additional, Czubkowski, Piotr, additional, Ordoñez, Felipe, additional, Candusso, Manila, additional, Aqul, Amal A., additional, Squires, Robert H., additional, Sokal, Etienne, additional, D’Agostino, Daniel, additional, Baumann, Ulrich, additional, D’Antiga, Lorenzo, additional, Kasi, Nagraj, additional, Laborde, Nolwenn, additional, Arikan, Cigdem, additional, Lin, Chuan-Hao, additional, Gilmour, Susan, additional, Mittal, Naveen, additional, Chiou, Fang Kuan, additional, Horslen, Simon P., additional, Huber, Wolf-Dietrich, additional, David-Feliciano, Susan, additional, Chien, Elaine, additional, Mogul, Douglas, additional, Garner, Will, additional, Nunes, Tiago, additional, Lascau, Anamaria, additional, Vig, Pamela, additional, Hupertz, Vera, additional, Gonzalez-Peralta, Regino, additional, Ekong, Udeme, additional, Hartley, Jane, additional, Laverdure, Noemie, additional, Ovchinsky, Nadia, additional, and Thompson, Richard, additional

Published
2023
Full Text
View/download PDF

7. Long-term maintenance of response and improved liver health with maralixibat in patients with progressive familial intrahepatic cholestasis (PFIC): data from the MARCH-ON study

Author

Miethke, Alexander, primary, Moukarzel, Adib, additional, Porta, Gilda, additional, Esquer, Joshue Covarrubias, additional, Czubkowski, Piotr, additional, Ordonez, Felipe, additional, Candusso, Manila, additional, Aqul, Amal A., additional, Squires, Robert H., additional, Sokal, Etienne, additional, D’Agostino, Daniel, additional, Baumann, Ulrich, additional, D’Antiga, Lorenzo, additional, Kasi, Nagraj, additional, Laborde, Nolwenn, additional, Arıkan, Cigdem, additional, Lin, Chuan-Hao, additional, Gilmour, Susan, additional, Mittal, Naveen, additional, Chiou, Fang Kuan, additional, Horslen, Simon P., additional, Huber, Wolf-Dietrich, additional, Nunes, Tiago, additional, Lascau, Anamaria, additional, Longpre, Lara, additional, Mogul, Douglas, additional, Aguilar, Raul, additional, Vig, Pamela, additional, Hupertz, Vera, additional, Gonzalez-Peralta, Regino, additional, Ekong, Udeme, additional, Hartley, Jane, additional, Laverdure, Noemie, additional, Ovchinsky, Nadia, additional, and Thompson, Richard, additional

Published
2023
Full Text
View/download PDF

10. Randomized, double-blind, placebo-controlled trial of Tenofovir Alafenamide in children and adolescents with chronic hepatitis B

Author

Schwarz, Kathleen, primary, Bezerra, Jorge, additional, Choe, Byung-Ho, additional, Lin, Chuan-Hao, additional, Abramov, Frida, additional, Nguyen, Anh-Hoa, additional, Liu, Yang, additional, Leisegang, Rory, additional, Flaherty, John F., additional, Pacurar, Daniela, additional, Kim, Kyung Mo, additional, Khaertynova, Shalimar, Ilsiyar, additional, Wu, Jia-Feng, additional, Tandon, Manish, additional, Rosenthal, Philip, additional, Viacheslav, Morozov, additional, Sokal, Etienne, additional, and Chang, Mei-Hwei, additional

Published
2022
Full Text
View/download PDF

11. Randomized, double-blind, placebo-controlled trial of Tenofovir Alafenamide in children and adolescents with chronic hepatitis B

Author

UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service de gastro-entérologie et hépatologie pédiatrique, Schwarz, Kathleen, Bezerra, Jorge, Choe, Byung-Ho, Lin, Chuan-Hao, Abramov, Frida, Nguyen, Anh-Hoa, Liu, Yang, Leisegang, Rory, Flaherty, John, Pacurar, Daniela, Kim, Kyung Mo, Khaertynova, Ilsiyar, Shalimar, Wu,Jia-Feng, Tandon, Manish, Rosenthal, Philip, Viacheslav, Morozov, Sokal, Etienne, Chang, Mei-Hwei, UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service de gastro-entérologie et hépatologie pédiatrique, Schwarz, Kathleen, Bezerra, Jorge, Choe, Byung-Ho, Lin, Chuan-Hao, Abramov, Frida, Nguyen, Anh-Hoa, Liu, Yang, Leisegang, Rory, Flaherty, John, Pacurar, Daniela, Kim, Kyung Mo, Khaertynova, Ilsiyar, Shalimar, Wu,Jia-Feng, Tandon, Manish, Rosenthal, Philip, Viacheslav, Morozov, Sokal, Etienne, and Chang, Mei-Hwei

Published
2022

13. Randomized, double-blind, placebo-controlled trial of Tenofovir Alafenamide in children and adolescents with chronic hepatitis B

Author

Schwarz, Kathleen, Bezerra, Jorge, Choe, Byung-Ho, Lin, Chuan-Hao, Abramov, Frida, Nguyen, Anh-Hoa, Liu, Yang, Leisegang, Rory, Flaherty, John, Pacurar, Daniela, Kim, Kyung Mo, Khaertynova, Ilsiyar, Shalimar, Wu,Jia-Feng, Tandon, Manish, Rosenthal, Philip, Viacheslav, Morozov, Sokal, Etienne, Chang, Mei-Hwei, UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, and UCL - (SLuc) Service de gastro-entérologie et hépatologie pédiatrique

Published
2022

15. P-6 SOFOSBUVIR CONTAINING REGIMENS ARE SAFE AND EFFECTIVE IN ADOLESCENTS WITH CHRONIC HEPATITIS C INFECTION

Author

Wirth, Stefan, Gonzalez-Peralta, Regino, Rosenthal, Philip, Hardikar, Winita, Wen, Jessica, Jonas, Maureen M., Mittal, Naveen, Whitworth, Mary, Arnon, Ronen, Lin, Chuan-Hao, Lobzin, Yury, Romero, Rene, Chulanov, Vladimir, Subbarao, Girish, Teckman, Jeffrey, Morozov, Vyacheslav, Bassetti, Eric, Kersey, Kathryn, Massetto, Benedetta, Zhu, Yanni, German, Polina, Brainard, Diana M., Bansal, Sanjay, Murray, Karen F., Schwarz, Kathleen, and Balistreri, William

Published
2021
Full Text
View/download PDF

16. Network Change Detection Based on Random Walk in Latent Space

Author

Lin, Chuan-Hao, Xu, Linchuan, and Yamanishi, Kenji

Abstract

The detection of network changes over time is based on identifying deviations of the network structure. The challenge mainly lies in designing a good summary or descriptor of the network structure for facilitating the measure of deviations. In particular, a network may have a huge number of nodes and edges. Moreover, there can exist complicated dependences among edges, e.g., the existence of some edges may be because of others. Therefore, it is non-trivial to measure the contribution of each node and each edge to the deviation of the entire network structure. Existing descriptors are designed to have factors less than the number of nodes and edges. They also model edge dependences, but can only achieve partial modeling. In this paper, we propose a novel type of descriptor. We first obtain node coordinates or positions in a latent space where nodes connected by edges have close positions by network embedding. Node positions are low-dimensional. More importantly, node positions can fully model edge dependences. We then design the descriptor based on random walk on the node positions. We conducted extensive experiments on synthetic datasets and three real-world datasets to demonstrate the effectiveness of our proposed change detection framework with the descriptor.

Published
2023
Full Text
View/download PDF

17. Sofosbuvir and Ribavirin Therapy for Children 3 to <12 Years Old With Hepatitis C Virus Genotype 2 or 3 Infection

Author

Rosenthal, Philip, Schwarz, Kathleen B., Gonzalez-Peralta, Regino P., Lin, Chuan-Hao, Kelly, Deidre A., Nightingale, Scott, Balistreri, William F., Bansal, Sanjay, Jonas, Maureen M., Massetto, Benedetta, Brainard, Diana M., Hsueh, Chia-Hsiang, Shao, Jiang, Parhy, Bandita, Davison, Suzanne, Feiterna-Sperling, Cornelia, Gillis, Lynette A., Indolfi, Giuseppe, Sokal, Etienne, Murray, Karen F., Wirth, Stefan, UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, and UCL - (SLuc) Service de gastro-entérologie et hépatologie pédiatrique

Subjects
Hepatology
Abstract

Currently, the only approved hepatitis C virus (HCV) treatment for children aged

Published
2020

18. WED-282 - Analysis of safety in maralixibat-treated participants with progressive familial intrahepatic cholestasis: data from MARCH-PFIC

Author

Miethke, Alexander, Moukarzel, Adib, Porta, Gilda, Esquer, Joshue Covarrubias, Czubkowski, Piotr, Ordoñez, Felipe, Candusso, Manila, Aqul, Amal A., Squires, Robert H., Sokal, Etienne, D’Agostino, Daniel, Baumann, Ulrich, D’Antiga, Lorenzo, Kasi, Nagraj, Laborde, Nolwenn, Arikan, Cigdem, Lin, Chuan-Hao, Gilmour, Susan, Mittal, Naveen, Chiou, Fang Kuan, Horslen, Simon P., Huber, Wolf-Dietrich, David-Feliciano, Susan, Chien, Elaine, Mogul, Douglas, Garner, Will, Nunes, Tiago, Lascau, Anamaria, Vig, Pamela, Hupertz, Vera, Gonzalez-Peralta, Regino, Ekong, Udeme, Hartley, Jane, Laverdure, Noemie, Ovchinsky, Nadia, and Thompson, Richard

Published
2023
Full Text
View/download PDF

19. LBP-35 - Long-term maintenance of response and improved liver health with maralixibat in patients with progressive familial intrahepatic cholestasis (PFIC): data from the MARCH-ON study

Author

Miethke, Alexander, Moukarzel, Adib, Porta, Gilda, Esquer, Joshue Covarrubias, Czubkowski, Piotr, Ordonez, Felipe, Candusso, Manila, Aqul, Amal A., Squires, Robert H., Sokal, Etienne, D’Agostino, Daniel, Baumann, Ulrich, D’Antiga, Lorenzo, Kasi, Nagraj, Laborde, Nolwenn, Arıkan, Cigdem, Lin, Chuan-Hao, Gilmour, Susan, Mittal, Naveen, Chiou, Fang Kuan, Horslen, Simon P., Huber, Wolf-Dietrich, Nunes, Tiago, Lascau, Anamaria, Longpre, Lara, Mogul, Douglas, Aguilar, Raul, Vig, Pamela, Hupertz, Vera, Gonzalez-Peralta, Regino, Ekong, Udeme, Hartley, Jane, Laverdure, Noemie, Ovchinsky, Nadia, and Thompson, Richard

Published
2023
Full Text
View/download PDF

20. Sofosbuvir and Ribavirin Therapy for Children 3 to <12 Years Old With Hepatitis C Virus Genotype 2 or 3 Infection

Author

UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service de gastro-entérologie et hépatologie pédiatrique, Rosenthal, Philip, Schwarz, Kathleen B., Gonzalez-Peralta, Regino P., Lin, Chuan-Hao, Kelly, Deidre A., Nightingale, Scott, Balistreri, William F., Bansal, Sanjay, Jonas, Maureen M., Massetto, Benedetta, Brainard, Diana M., Hsueh, Chia-Hsiang, Shao, Jiang, Parhy, Bandita, Davison, Suzanne, Feiterna-Sperling, Cornelia, Gillis, Lynette A., Indolfi, Giuseppe, Sokal, Etienne, Murray, Karen F., Wirth, Stefan, UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service de gastro-entérologie et hépatologie pédiatrique, Rosenthal, Philip, Schwarz, Kathleen B., Gonzalez-Peralta, Regino P., Lin, Chuan-Hao, Kelly, Deidre A., Nightingale, Scott, Balistreri, William F., Bansal, Sanjay, Jonas, Maureen M., Massetto, Benedetta, Brainard, Diana M., Hsueh, Chia-Hsiang, Shao, Jiang, Parhy, Bandita, Davison, Suzanne, Feiterna-Sperling, Cornelia, Gillis, Lynette A., Indolfi, Giuseppe, Sokal, Etienne, Murray, Karen F., and Wirth, Stefan

Abstract

Currently, the only approved hepatitis C virus (HCV) treatment for children aged <12 years is pegylated-interferon plus ribavirin. In an open-label study, we evaluated the safety and efficacy of sofosbuvir plus ribavirin for 12 weeks in children aged 3 to <12 years chronically infected with genotype 2 or for 24 weeks in patients with genotype 3. Patients aged 3 to <6 years weighing <17 kg received sofosbuvir 150 mg, and patients aged 3 to <6 years weighing ≥17 kg and all patients aged 6 to <12 years received sofosbuvir 200 mg once daily. Intensive pharmacokinetic sampling conducted in each age group confirmed the appropriateness of sofosbuvir doses. For all patients, ribavirin dosing was determined by baseline weight (up to 1400 mg/day, two divided doses). The primary efficacy endpoint was sustained virologic response 12 weeks after therapy (SVR12). 54 patients were enrolled (41 aged 6 to <12 years and 13 aged 3 to <6 years). Most were treatment-naive (98%) and infected perinatally (94%). All but one patient achieved SVR12 (53/54, 98%, 95% CI 90-100%). The patient who did not achieve SVR12 was a 4 year-old who discontinued treatment after three days due to 'abnormal drug taste'. The most commonly reported adverse events in patients aged 6 to <12 years were vomiting (32%) and headache (29%) and in patients aged 3 to <6 years, vomiting (46%) and diarrhea (39%). One 3 year-old patient had a serious adverse event of accidental ribavirin overdose requiring hospitalization for monitoring; this patient completed treatment and achieved SVR12. CONCLUSION: Sofosbuvir plus ribavirin was well-tolerated and highly effective in children aged 3 to <12 years with chronic HCV genotype 2 or 3 infection

Published
2020

23. IDDF2020-ABS-0059 Safety and efficacy of sofosbuvir/velpatasvir (SOF/VEL) in pediatric patients 6 to < 18 years old with chronic hepatitis C (CHC) infection

Author

Jonas, Maureen, primary, Romero, Rene, additional, Sokal, Etienne, additional, Rosenthal, Philip, additional, Verucchi, Gabriella, additional, Lin, Chuan-Hao, additional, Wen, Jessica, additional, Narkewicz, Michael, additional, Bansal, Sanjay, additional, Shao, Jiang, additional, Hsueh, Sean, additional, Gaggar, Anuj, additional, Kersey, Kathryn, additional, Kwan Chan, Carol Yee, additional, Gonzalez-Peralta, Regino, additional, Leung, Daniel, additional, Balistreri, William, additional, Murray, Karen, additional, and Schwarz, Kathleen, additional

Published
2020
Full Text
View/download PDF

25. Early weaning induces jejunal ornithine decarboxylase and cell proliferation in neonatal rats

Author

Lin, Chuan-Hao, Correia, Leena, Tolia, Ketan, Gesell, Mark S., Tolia, Vasundhara, Lee, Ping-Cheung, and Luk, Gordon D.

Subjects
Ornithine decarboxylase -- Health aspects, Intestines -- Research, Infants -- Weaning, Cell proliferation -- Health aspects, Rats as laboratory animals -- Research, Food/cooking/nutrition
Abstract

Increased ornithine decarboxylase (ODC) activity is associated with rapid cell proliferation in many cell types. The cellular effects of early weaning on intestinal development are not well established. To investigate whether ODC is involved in intestinal growth after early weaning, we precociously weaned suckling rats on postnatal d 15 and followed through d 21 (6 d after early weaning). Age-matched suckling pups served as controls. Rat pups were killed 1, 2, 3 and 6 d after early weaning and jejunal mucosa was assayed for ODC and sucrase activities, and protein and DNA contents. Jejunal cell proliferation was monitored by bromodeoxyuridine immunohistochemistry. Elevated jejunal ODC activity 1 d after early weaning was the earliest cellular event that was detected in the current study. ODC activity peaked at d 3 (about 15-fold greater than age-matched unweaned suckling controls). Sucrase activity was elevated at d 2 after weaning and peaked at d 3 (about 10-fold greater than controls). Greater bromodeoxyuridine immunostaining in early weaned rats occurred on d 3. Protein and DNA contents were greater in jejunal mucosa of early weaned rats at d 6. Serum corticosterone levels were elevated on d I and d 2 after early weaning compared to controls. To explore whether the intake of nonpurified diet played a role, we also compared the induction of jejunal ODC activity in early weaned pups and pups that were food-deprived for 1 d. ODC activity was not greater in the food-deprived group compared to suckling controls while the early weaned group had 6-fold greater activity I d after early weaning. Early weaning stimulates jejunal cell proliferation and differentiation. The temporal sequence of increased ODC activity followed by increases in other growth variables suggests that the induction of ODC activity may act as an early marker of intestinal growth during early weaning. KEY WORDS: * rats * weaning * ornithine decarboxylase * intestinal growth * cell proliferation

Published
1998

28. Severe Late-Onset Acute Cellular Rejection in a Pediatric Patient With Isolated Small Intestinal Transplant Rescued With Aggressive Immunosuppressive Approach: A Case Report

Author

Narang, Amrita, primary, Xi, Dong, additional, Mitsinikos, Tania, additional, Genyk, Yuri, additional, Thomas, Dan, additional, Kohli, Rohit, additional, Lin, Chuan-Hao, additional, Soufi, Nisreen, additional, Warren, Mikako, additional, Merritt, Russell, additional, and Yanni, George, additional

Published
2019
Full Text
View/download PDF

29. A Prospective Trial of Withdrawal and Reinstitution of Ursodeoxycholic Acid in Pediatric Primary Sclerosing Cholangitis

Author

Black, Dennis D., primary, Mack, Cara, additional, Kerkar, Nanda, additional, Miloh, Tamir, additional, Sundaram, Shikha S., additional, Anand, Ravinder, additional, Gupta, Ashutosh, additional, Alonso, Estella, additional, Arnon, Ronen, additional, Bulut, Pinar, additional, Karpen, Saul, additional, Lin, Chuan‐Hao, additional, Rosenthal, Philip, additional, Ryan, Matthew, additional, Squires, Robert H., additional, Valentino, Pamela, additional, Elsea, Sarah H., additional, and Shneider, Benjamin L., additional

Published
2019
Full Text
View/download PDF

30. Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection

Author

Rosenthal, Philip, primary, Schwarz, Kathleen B., additional, Gonzalez‐Peralta, Regino P., additional, Lin, Chuan‐Hao, additional, Kelly, Deidre A., additional, Nightingale, Scott, additional, Balistreri, William F., additional, Bansal, Sanjay, additional, Jonas, Maureen M., additional, Massetto, Benedetta, additional, Brainard, Diana M., additional, Hsueh, Chia‐Hsiang, additional, Shao, Jiang, additional, Parhy, Bandita, additional, Davison, Suzanne, additional, Feiterna‐Sperling, Cornelia, additional, Gillis, Lynette A., additional, Indolfi, Giuseppe, additional, Sokal, Etienne M., additional, Murray, Karen F., additional, and Wirth, Stefan, additional

Published
2019
Full Text
View/download PDF

31. Safety and Efficacy of Ledipasvir–Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6‐11

Author

Murray, Karen F., primary, Balistreri, William F., additional, Bansal, Sanjay, additional, Whitworth, Suzanne, additional, Evans, Helen M., additional, Gonzalez‐Peralta, Regino P., additional, Wen, Jessica, additional, Massetto, Benedetta, additional, Kersey, Kathryn, additional, Shao, Jiang, additional, Garrison, Kimberly L., additional, Parhy, Bandita, additional, Brainard, Diana M., additional, Arnon, Ronen, additional, Gillis, Lynette A., additional, Jonas, Maureen M., additional, Lin, Chuan‐Hao, additional, Narkewicz, Michael R., additional, Schwarz, Kathleen, additional, and Rosenthal, Philip, additional

Published
2018
Full Text
View/download PDF

32. Mo1446 - Initial Results of the Wuppsc Study – Prospective Multicenter Withdrawal of Ursodeoxycholic Acid in Pediatric Primary Sclerosing Cholangitis (PSC)

Author

Black, Dennis D., primary, Mack, Cara L., additional, Kerkar, Nanda, additional, Miloh, Tamir, additional, Sundaram, Shikha S., additional, Anand, Ravinder, additional, Gupta, Ashutosh, additional, Alonso, Estella, additional, Arnon, Ronen, additional, Bulut, Pinar, additional, Karpen, Saul J., additional, Lin, Chuan-Hao, additional, Rosenthal, Philip, additional, Ryan, Matthew, additional, Squires, Robert H., additional, Valentino, Pamela L., additional, and Shneider, Benjamin L., additional

Published
2018
Full Text
View/download PDF

34. The safety and effectiveness of ledipasvir−sofosbuvir in adolescents 12‐17 years old with hepatitis C virus genotype 1 infection

Author

Balistreri, William F., primary, Murray, Karen F., additional, Rosenthal, Philip, additional, Bansal, Sanjay, additional, Lin, Chuan‐Hao, additional, Kersey, Kathryn, additional, Massetto, Benedetta, additional, Zhu, Yanni, additional, Kanwar, Bittoo, additional, German, Polina, additional, Svarovskaia, Evguenia, additional, Brainard, Diana M., additional, Wen, Jessica, additional, Gonzalez‐Peralta, Regino P., additional, Jonas, Maureen M., additional, and Schwarz, Kathleen, additional

Published
2017
Full Text
View/download PDF

35. Utility of hepatobiliary scintigraphy in diagnosing or excluding biliary atresia in premature neonates and full-term infants with conjugated hyperbilirubinemia who received parenteral nutrition.

Author

Barseghyan, Karine, Ramanathan, Rangasamy, Chavez, Thomas, Harlan, Susan, Lin, Chuan-Hao, Mitsinikos, Tania, and McLean, Claire

Subjects
NEWBORN infants, HYPERBILIRUBINEMIA, BILIARY atresia, GASTROENTEROLOGY, PEDIATRICS
Abstract

Purpose: Hepatobiliary scintigraphy (HBS) is used to aid in the diagnosis of Biliary Atresia in full-term infants with conjugated hyperbilirubinemia. There is little information on the utility of the HBS in premature infants with conjugated hyperbilirubinemia and infants with parenteral nutrition associated cholestasis (PNAC). The purpose of this study is to assess the utility of HBS in differentiating Biliary Atresia and PNAC in premature neonates and full-term infants who received parenteral nutrition (PN). Materials and methods: Retrospective data collection and analysis on infants who developed conjugated hyperbilirubinemia and had HBS performed during their stay at level IV neonatal intensive care unit between 2005 and 2015. Results: A total of 20 patients with exposure to PN had HBS; two patients were confirmed to have Biliary Atresia. There were no statistically significant differences between patients with Biliary Atresia versus PNAC in demographics, days on PN, or gamma glutamyl-transferase levels. Stool color was statistically significantly different between the two groups; patients with Biliary Atresia had acholic stools more consistently than patients without Biliary Atresia. HBS had 100% sensitivity, 17% specificity, positive-predictive value of 12%, and a negative-predictive value (NPV) of 100%. Conclusions: These data indicate that the ability of HBS to aid in diagnosing Biliary Atresia is poor in a population of preterm neonates and full-term infants with PNAC. Although there is 100% sensitivity, the poor specificity (17%) should be acknowledged when utilizing HBS to diagnose Biliary Atresia in this vulnerable patient population. NPV of 100% is helpful in ruling out Biliary Atresia in this population. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results